Academics

Cancer Research

Working Toward a Cure

Our researchers contribute to the South Carolina Central Cancer Registry and have partnered with the MUSC Hollings Cancer Center to stay up-to-date on the latest clinical trials and treatments.

Current Trials

Bladder Cancer

Back to Top

Cysview

Description

The purpose of the study is to gather more information on the current use of Blue Light Cystoscopy™ with Cysview® in urologists' practices. This trial is a registry study for patients with bladder cancer who undergo cystoscopy. Cysview is an FDA approved drug imaging agent that is absorbed by malignant cells causing them to appear pink under blue light thus making them easier to see.

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 5/20/2022

Location: Lexington Urology

Breast Cancer

Back to Top

SERENA-6

Description
This study is intended to show the superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Open to enrollment.

Posted By: Dr. Steven Madden

Posted Date: 11/2/2022

Location: Lexington Medical Cancer Center

A011801

Description
The Compassher2 Trials (Comprehensive Use Of Pathologic Response Assessment To Optimize Therapy In Her2-Positive Breast Cancer): Compassher2 Residual Disease (Rd), A Double-Blinded, Phase Iii Randomized Trial Of T-Dm1 And Placebo Compared With T-Dm1 And Tucatinib.

This trial studies how well trastuzumab emtanzine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Giving T-DMI and tucatinib together may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. 

Open to enrollment 

Posted By: Dr. Steven Madden

Posted Date: 9/27/2019

Location: Lexington Medical Cancer Center

MA.39 Tailor RT

Description
A randomized trial of regional radiotherapy in biomarker low risk node positive breast cancer.

Posted By: Dr. Davis

Posted Date: 9/5/2019

Location: Lexington Medical Cancer Center

Head & Neck Cancer

Back to Top

Lung Cancer

Back to Top

Alchemist - 081801

Description
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer.

Open to enrollment

Posted By: Dr. James Wells

Posted Date: 9/30/2022

Location: Lexington Medical Cancer Center

Emerge 402

Description
Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Open to enrollment

Posted By: Dr. Steven Madden

Posted Date: 11/1/2021

Location: Lexington Medical Cancer Center

Alchemist - A151216

Description
Genetic Testing For Patients with Resectable or Resected Lung Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial 

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 3/15/2015

Location: Lexington Medical Cancer Center

Alchemist - E4512

Description
Testing the Addition of the Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 5/16/2016

Location: Lexington Medical Cancer Center

Prostate Cancer

Back to Top

BRAT

Description
The purpose of the Prostate BRAchyTherapy (BRAT) Registry is to measure clinical outcomes of patients treated with Brachytherapy at Lexington Medical Center (LMC).

Open to enrollment

Posted By: Dr. Quillin Davis

Posted Date: 11/1/2021

Location: Lexington Medical Cancer Center

EA8184

Description
To Evaluate if Green Tea can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring.

This study is being done to answer the following question:  Can we lower the chance of your prostate cancer growing by adding Sunphenon® 90D (containing green tea catechins) by closely monitoring your prostate cancer?

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 11/1/2021

Location: Lexington Urology